TY - JOUR
T1 - Evaluation of very high-and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration
AU - Nguyen, Quan Dong
AU - Campochiaro, Peter A.
AU - Shah, Syed Mahmood
AU - Browning, David J.
AU - Hudson, Henry L.
AU - Sonkin, Peter L.
AU - Hariprasad, Seenu M.
AU - Kaiser, Peter K.
AU - Slakter, Jason
AU - Haller, Julia A.
AU - Do, Diana V.
AU - Mieler, William
AU - Chu, Karen
AU - Ingerman, Avner
AU - Vitti, Robert
AU - Berliner, Alyson J.
AU - Cedarbaum, Jesse
PY - 2012/12/1
Y1 - 2012/12/1
N2 - Purpose: To determine bioactivity and duration of effect of intravitreal aflibercept injection (also known as vascular endothelial growth factor Trap-Eye) for neovascular age-related macular degeneration (AMD). Methods: In this double-masked, phase 1 study, 28 patients with lesions ≤12 disc areas, ≥50% active choroidal neovascularization (CNV), and best corrected visual acuity (BCVA) ≤20/40 were randomized 1:1 to a single intravitreal injection of aflibercept 0.15 or 4mg. The primary end point was the change from baseline in central retinal/lesion thickness (CR/LT) at week-8. Secondary outcomes were the change from baseline BCVA, the change in CNV lesion size and area of leakage, and proportion of patients requiring repeat injection at 8 weeks. Results: Mean percent decrease in CR/LT for the 4-mg and 0.15-mg groups was, respectively, 34.2 versus 13.3 at week 4 (P=0.0065), 23.8 versus 5.9 at week 6 (P=0.0380), and 25.2% versus 11.3% at week 8 (P=0.150). The 4-mg group gained a mean of 4.5 letters in BCVA (6/14 patients gaining ≥10 letters) versus 1.1 letters in 0.15-mg group (1/14 gaining ≥10 letters) at week 8. Fewer patients needed retreatment in the 4-mg group at week 8. No serious adverse event or ocular inflammation was reported in either group. Conclusions: Intravitreal aflibercept 4mg had a safety profile similar to that of the very low dose 0.15mg, and was well-tolerated. The 4-mg dose significantly reduced foveal thickening at weeks 4 and 6, significantly improved BCVA at weeks 6, and reduced the need for repeat injection after 8 weeks compared with intravitreal aflibercept 0.15mg in neovascular AMD patients.
AB - Purpose: To determine bioactivity and duration of effect of intravitreal aflibercept injection (also known as vascular endothelial growth factor Trap-Eye) for neovascular age-related macular degeneration (AMD). Methods: In this double-masked, phase 1 study, 28 patients with lesions ≤12 disc areas, ≥50% active choroidal neovascularization (CNV), and best corrected visual acuity (BCVA) ≤20/40 were randomized 1:1 to a single intravitreal injection of aflibercept 0.15 or 4mg. The primary end point was the change from baseline in central retinal/lesion thickness (CR/LT) at week-8. Secondary outcomes were the change from baseline BCVA, the change in CNV lesion size and area of leakage, and proportion of patients requiring repeat injection at 8 weeks. Results: Mean percent decrease in CR/LT for the 4-mg and 0.15-mg groups was, respectively, 34.2 versus 13.3 at week 4 (P=0.0065), 23.8 versus 5.9 at week 6 (P=0.0380), and 25.2% versus 11.3% at week 8 (P=0.150). The 4-mg group gained a mean of 4.5 letters in BCVA (6/14 patients gaining ≥10 letters) versus 1.1 letters in 0.15-mg group (1/14 gaining ≥10 letters) at week 8. Fewer patients needed retreatment in the 4-mg group at week 8. No serious adverse event or ocular inflammation was reported in either group. Conclusions: Intravitreal aflibercept 4mg had a safety profile similar to that of the very low dose 0.15mg, and was well-tolerated. The 4-mg dose significantly reduced foveal thickening at weeks 4 and 6, significantly improved BCVA at weeks 6, and reduced the need for repeat injection after 8 weeks compared with intravitreal aflibercept 0.15mg in neovascular AMD patients.
UR - http://www.scopus.com/inward/record.url?scp=84869401366&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869401366&partnerID=8YFLogxK
U2 - 10.1089/jop.2011.0261
DO - 10.1089/jop.2011.0261
M3 - Article
C2 - 22775078
AN - SCOPUS:84869401366
SN - 1080-7683
VL - 28
SP - 581
EP - 588
JO - Journal of Ocular Pharmacology and Therapeutics
JF - Journal of Ocular Pharmacology and Therapeutics
IS - 6
ER -